Another Neulasta biosimilar drug on the market

On June 11, Pfizer announced that the U.SFDA had approved Nyvepria (pegfilgrastim-apgf, Pefegrin), specific indications for non-myelin malignant tumor patients who are being treated with a clinically significant incidence of febrile neutrophils reduction drugs (such as chemotherapy) to reduce the incidence of infection, characterized by a decrease in febrile neutrophilsNyvepria, a biosimilar to Thein-branded drug Neulasta, said it plans to bring the product to the U.Smarket later this yearThe FDA's approval of Nyvepria is based on a review of a comprehensive packet and all the evidence that Nyvepria is highly similar to its reference product NeulastaNyvepria is also under review by the European Medicines Agency (EMA)In the U.S., Pfizer has approved nine biosimilar drugs, six of which are cancer-like drugs, and the remaining three are specifically approved for supportive care for cancer patientsIn July 2018, Pfizer's Nivestym (filgrastim-aafi, non-gesting) was approved by the FDA as a biosimilar to Neupogen, another branded drugTo date, the FDA has approved four Neulasta biosimilars and two Neupogen biosimilarsNeupogen is a recombinant human granulocytopha cluster irritant (G-CSF), a "whitening" drug that increases the number of white blood cells in a patient's bodyNeulasta is a long-acting version of Neupogen that extends the metabolism of the drug in the body through polyethyl glycolation (PEG) modificationNeulasta's global sales in 2019 were $3.221 billion ($2.814 billion) in the U.Smarket, down 28 percent from the previous year, while Neupogen's global sales in 2019 were $264 million ($178 million in the U.S.), down 28 percent from the previous year, according to Amgen's earnings reportSource: FDA Approves Pfizer's Oncology SupportIve Care Biolike, NYVEPRIA™ (pegfilgrastim-apgf)